Joseph T. Coyle

Last updated
Joseph T. Coyle
Born (1943-10-09) October 9, 1943 (age 80)
Chicago, Illinois, U.S.
NationalityAmerican
Alma mater College of the Holy Cross (BA)
University of Paris
Johns Hopkins University (MD)
Awards John J. Abel Award (1979)
Sarnat Prize (2017)
Scientific career
Fields Neurobiology
Institutions National Institutes of Health
Johns Hopkins University

Joseph Thomas Coyle Jr. [1] (born October 9, 1943) is an American psychiatrist and neuroscientist. He is the Eben S. Draper Professor of Psychiatry and Neuroscience at Harvard Medical School. [2]

Contents

Coyle is known for his work on the neurobiology of mental illness, more specifically on schizophrenia. He was President of the Society of Neuroscience from 1991–1992, and also the president of the American College of Neuropsychopharmacology in 2001. He is a member of the Institute of Medicine.

Early life and education

Coyle was born on October 9, 1943, in Chicago, Illinois. [3] Several members of Coyle's family were physicians, including uncles and cousins. His maternal grandfather, a doctor in Iowa, was an immigrant from Luxembourg who attended Rush Medical College. Coyle's father, an orthopedic surgeon, was the team physician for the Chicago White Sox. [4]

Coyle was raised in the South Side of Chicago. As a child, he owned a chemistry set and took courses in taxidermy. He attended a Jesuit high school and then enrolled at the College of the Holy Cross, where he majored in French and philosophy. [5] The college's curriculum required years of classical Greek, Latin, and French. [4] Coyle spent a formative year abroad studying at the University of Paris in France. Upon returning to Holy Cross, he wrote his senior thesis on Irish playwright Samuel Beckett, graduating with a Bachelor of Arts (B.A.) in 1965. [6] He later recalled the college's focus in literature, languages, and philosophy as having "greatly transformed my view of the world and solidified my interests in art, music, and literature". [7]

Inspired by Sigmund Freud, Jacques Lacan, and Jean-Paul Sartre, Coyle became a psychiatric orderly at a local community hospital during the summer after college. When the brother of a friend was admitted due to paranoid delusions, Coyle resolved to study psychiatry in medical school. He studied medicine at Johns Hopkins University and attended lectures by Leon Eisenberg, Jerome Frank, Robert Cooke, Seymour Kety, and Curt Richter. [7] In his second year, Coyle was influenced by neuroscientist Solomon Snyder, who taught psychopharmacology, and became an assistant in Snyder's laboratory. [8] He received a scholarship to remain under Snyder at the Johns Hopkins School of Medicine, obtaining his Doctor of Medicine (M.D.) in 1969. [9]

Subsequently he completed an internship in pediatrics, followed by a residency in psychiatry from 1973 until 1976. During this time period, Coyle worked with Julius Axelrod, a Nobel laureate, known for his research on catecholamines, which include epinephrine and norepinephrine. [2] [10]

Academia and clinical careers

Coyle is the current Chair of Psychiatry and Neuroscience at Harvard Medical School. He became a member of the National Academy of Medicine in 1990, a fellow of Arts and Sciences, and of the American Psychiatric Association. From 1991 to 2001, he was the Chair of the Consolidated Department of Psychiatry, also at Harvard. Before beginning work for Harvard Medical School in 1991, Coyle was a professor of Child Psychiatry at Johns Hopkins, where he began in 1975, and was eventually named the Distinguished Service Professor of Child Psychiatry in 1985. During his clinical career Coyle established a basis combining neuroscience and clinical psychiatry studies, where he has contributed to the understanding of certain neuropsychiatric disorders such as schizophrenia and bipolar disorder. His studies of these disorders lead him to the discovery of neurological mechanisms underlying diseases such as Huntingtons and Alzheimers. [10]

Coyle was president of the Society for Neuroscience from 1991-1992 and the president of the American College of Neuropsychopharmacology in 2001. He was the Editor-in-Chief of the Archives of General Psychiatry from 2001-2014. [11]

Research

Comparison between a non-schizophrenic brain and a schizophrenic brain Schizophrenia (Illustration).png
Comparison between a non-schizophrenic brain and a schizophrenic brain

Coyle is the current Director of the Laboratory for Psychiatric and Molecular Neuroscience. Though he has earned recognition for work in numerous areas of neurobiology and psychopharmacology, an area of research that Coyle has earned distinction in is that of the neurotransmitter glutamate. Coyle has studied glutamate's excitatory effects on the brain along with the role this neurotransmitter plays in common mental illnesses, primarily in schizophrenia. A main focus of research for Coyle and his associates is the understanding of the neuromolecular mechanisms underlying psychiatric disorders, being able to understand how these mechanisms affect the brain and overall behavior, as well as aid in development of efficient and effective treatment methods. Coyle focused his attention specifically on schizophrenia and bipolar disorder, Huntington’s, and Alzheimer's disease. He was one of the first scientists to ever identify structural abnormalities in bipolar disorder, similar to schizophrenia. Coyle’s lab aims to mimic the neuromolecular mechanisms underlying these disorders in model organisms such as mice, who have similar nervous systems to humans. One way they do this is by targeting the N-methyl-D-aspartate receptor (NMDAR), which has a vital role in transmission of excitatory information within numerous brain pathways and structures. Results from these targeted experiments indicated that when genes encoding these NMDARs were altered, the resulting chemical pathways and behavioral traits in the model organisms mimicked those found/seen in schizophrenia patients. Such research can be beneficial to science/medical research because, In doing these experiments, they can target glutamatergic transmission pathways associated with mental illnesses like schizophrenia, and develop treatments that target and reverse/prevent the damage caused by such pathways, as well as provide a better overall understanding of a wide variety of mental conditions. For example, the work Coyle’s lab published regarding the role of NMDARs in schizophrenia led to testing of NMDAR-restoring medications, which resulted in reversal of damage to functional pathways, as well as overall improvement in behavior and cognitive abilities. [12] [10]

Awards and honors

Publications

His most cited papers are:

Related Research Articles

Serine is an α-amino acid that is used in the biosynthesis of proteins. It contains an α-amino group, a carboxyl group, and a side chain consisting of a hydroxymethyl group, classifying it as a polar amino acid. It can be synthesized in the human body under normal physiological circumstances, making it a nonessential amino acid. It is encoded by the codons UCU, UCC, UCA, UCG, AGU and AGC.

<span class="mw-page-title-main">NMDA receptor</span> Glutamate receptor and ion channel protein found in nerve cells

The N-methyl-D-aspartatereceptor (also known as the NMDA receptor or NMDAR), is a glutamate receptor and ion channel found in neurons. The NMDA receptor is one of three types of ionotropic glutamate receptors, the other two being AMPA and kainate receptors. Depending on its subunit composition, its ligands are glutamate and glycine (or D-serine). However, the binding of the ligands is typically not sufficient to open the channel as it may be blocked by Mg2+ ions which are only removed when the neuron is sufficiently depolarized. Thus, the channel acts as a “coincidence detector” and only once both of these conditions are met, the channel opens and it allows positively charged ions (cations) to flow through the cell membrane. The NMDA receptor is thought to be very important for controlling synaptic plasticity and mediating learning and memory functions.

Neuropsychiatry is a branch of medicine that deals with psychiatry as it relates to neurology, in an effort to understand and attribute behavior to the interaction of neurobiology and social psychology factors. Within neuropsychiatry, the mind is considered "as an emergent property of the brain", whereas other behavioral and neurological specialties might consider the two as separate entities. Those disciplines are typically practiced separately.

The biopsychiatry controversy is a dispute over which viewpoint should predominate and form a basis of psychiatric theory and practice. The debate is a criticism of a claimed strict biological view of psychiatric thinking. Its critics include disparate groups such as the antipsychiatry movement and some academics.

<i>N</i>-Acetylaspartylglutamic acid Peptide neurotransmitter

N-Acetylaspartylglutamic acid is a peptide neurotransmitter and the third-most-prevalent neurotransmitter in the mammalian nervous system. NAAG consists of N-acetylaspartic acid (NAA) and glutamic acid coupled via a peptide bond.

Gliotransmitters are chemicals released from glial cells that facilitate neuronal communication between neurons and other glial cells. They are usually induced from Ca2+ signaling, although recent research has questioned the role of Ca2+ in gliotransmitters and may require a revision of the relevance of gliotransmitters in neuronal signalling in general.

<span class="mw-page-title-main">Quinolinic acid</span> Dicarboxylic acid with pyridine backbone

Quinolinic acid, also known as pyridine-2,3-dicarboxylic acid, is a dicarboxylic acid with a pyridine backbone. It is a colorless solid. It is the biosynthetic precursor to niacin.

<span class="mw-page-title-main">Kenneth L. Davis</span>

Kenneth L. Davis is the executive vice chairperson of the board of trustees at the Mount Sinai Health System in New York City, and an American author and medical researcher who developed the Alzheimer's Disease Assessment Scale, the most widely used tool to test the efficacy of treatments for Alzheimer's disease designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic to persons with Alzheimer's disease. His research led to four of the first five FDA-approved drugs for Alzheimer's.

Richard Lewis Huganir is a Bloomberg Distinguished Professor in the Departments of Neuroscience and Psychological and Brain Sciences, Director of the Solomon H. Snyder Department of Neuroscience, and co-director of the Johns Hopkins Medicine Brain Science Institute at the Johns Hopkins University School of Medicine. He has joint appointments in the Department of Biological Chemistry and the Department of Pharmacology and Molecular Sciences in the Johns Hopkins School of Medicine.

Joseph D. Buxbaum is an American molecular and cellular neuroscientist, autism researcher, and the Director of the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai. Buxbaum is also, along with Simon Baron-Cohen, the co-editor of the BioMed Central journal Molecular Autism, and is a member of the scientific advisory board of the Autism Science Foundation. Buxbaum is a Professor of Psychiatry, Neuroscience, and Genetics and Genomic Sciences. He is also the Vice Chair for Research and for Mentoring in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai.

Sir Michael John Owen FRCPsych FMedSci FLSW is a Welsh research scientist in the area of psychiatry, currently the head of the Division of Psychological Medicine and Clinical Neurosciences at Cardiff University.

Paul Thompson is a professor of neurology at the Imaging Genetics Center at the University of Southern California. Thompson obtained a bachelor's degree in Greek and Latin languages and mathematics from Oxford University. He also earned a master's degree in mathematics from Oxford and a PhD degree in neuroscience from University of California, Los Angeles.

<span class="mw-page-title-main">Hilmar Bading</span> German physician and neuroscientist

Hilmar Bading is a German physician and neuroscientist. He is a member of the German National Academy of Science Leopoldina.

Extrasynaptic NMDA receptors are glutamate-gated neurotransmitter receptors that are localized to non-synaptic sites on the neuronal cell surface. In contrast to synaptic NMDA receptors that promote acquired neuroprotection and synaptic plasticity, extrasynaptic NMDA receptors are coupled to activation of death-signaling pathways. Extrasynaptic NMDA receptors are responsible for initiating excitotoxicity and have been implicated in the etiology of neurodegenerative diseases, including stroke, Huntington’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).

Daniel R. Weinberger is a professor of psychiatry, neurology and neuroscience at Johns Hopkins University and Director and CEO of the Lieber Institute for Brain Development, which opened in 2011.

<span class="mw-page-title-main">Ganesan Venkatasubramanian</span> Indian psychiatrist and clinician

Ganesan Venkatasubramanian is an Indian psychiatrist and clinician-scientist who works as a professor of psychiatry at the National Institute of Mental Health and Neurosciences, Bangalore (NIMHANS). His overarching research interest to learn the science that will facilitate a personalized approach to understand and treat severe mental disorders like schizophrenia. Venkatasubramanian is known for his studies in the fields of schizophrenia, transcranial Direct Current Stimulation (tDCS), brain imaging, neuroimmunology, neurometabolism and several other areas of biological psychiatry. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards, for his contributions to medical sciences in 2018. He was also one of the collaborating scientists in the NIMHANS-IOB Bioinformatics and Proteomics laboratory of the Institute of Bioinformatics (IOB) in Bangalore and NIMHANS. Besides, he is an adjunct faculty at the Centre for Brain Research (CBR) in Bangalore.

Stephen F. Heinemann (1939–2014) was a professor of neuroscience at the Salk Institute. He was an early researcher in the field of molecular neuroscience, contributing to the current knowledge of how nerves communicate with each other, and the role of neurotransmitters. Stephen Heinemann died August 6, 2014, of kidney failure.

<span class="mw-page-title-main">Bita Moghaddam</span> Iranian-American neuroscientist

Bita Moghaddam is an Iranian-American neuroscientist and author. She is currently the Ruth Matarazzo Professor of Behavioral Neuroscience at Oregon Health & Science University. Moghaddam investigates the neuronal processes underlying emotion and cognition as a first step to designing strategies to treat and prevent brain illnesses.

<span class="mw-page-title-main">Carolyn I. Rodriguez</span> Puerto Rican psychiatrist

Carolyn I. Rodriguez is a Puerto Rican psychiatrist, neuroscientist, and clinical researcher developing treatments for obsessive compulsive disorder as well as mapping circuit dysfunction in the human brain. Rodriguez holds appointments in both clinical and academic departments at Stanford University. Rodriguez is a Clinical Lab Director at the Stanford Center for Cognitive and Neurobiological Imaging, an associate professor and Associate Chair of Psychiatry and Behavioral Sciences, and a Director of several specialized translational research programs.

<span class="mw-page-title-main">Scott A. Small</span> American neurologist and neuroscientist

Scott A. Small is an American neurologist and neuroscientist known for his work in Alzheimer's disease and normal cognitive aging. His research focuses on the hippocampus, a circuit in the brain targeted by Alzheimer's disease, aging, and schizophrenia. Small is the Director of the Alzheimer's Disease Research Center at Columbia University, where he is the Boris and Rose Katz Professor of Neurology. He is also appointed in Radiology and in Psychiatry, where he directs the Schizophrenia Research program.

References

  1. ↑ "Doctors of Medicine". Conferring of Degrees at the close of the ninety-third academic year (PDF). Baltimore, Maryland: The Johns Hopkins University. June 6, 1969. p. 39. Retrieved 2020-11-04.
  2. 1 2 Coyle, Joseph T. (1989), "Alzheimer's Disease", Abnormal States of Brain and Mind, Birkhäuser Boston, pp. 9–10, doi:10.1007/978-1-4899-6768-8_4, ISBN   978-1-4899-6770-1
  3. ↑ Squire, Albright & Coyle, p. 193.
  4. 1 2 Squire, Albright & Coyle, p. 194.
  5. ↑ Squire, Albright & Coyle, p. 193, 195.
  6. ↑ Squire, Albright & Coyle, p. 195, 193.
  7. 1 2 Squire, Albright & Coyle, p. 195.
  8. ↑ Squire, Albright & Coyle, p. 196.
  9. ↑ Squire, Albright & Coyle, p. 197, 193.
  10. 1 2 3 "Joseph T. Coyle, MD | McLean Hospital". www.mcleanhospital.org. Retrieved 2020-03-31.
  11. ↑ "JAMA Psychiatry". 77 (4). 2020: 336. doi: 10.1001/jamapsychiatry.2019.2795 . S2CID   221569798.{{cite journal}}: Cite journal requires |journal= (help)
  12. ↑ "Joseph T. Coyle, M.D." Brain & Behavior Research Foundation. 2017-03-31. Retrieved 2020-03-31.
  13. ↑ "Julius Axelrod Prize".
  14. ↑ "Joseph Coyle | Harvard Catalyst Profiles | Harvard Catalyst". connects.catalyst.harvard.edu. Retrieved 2020-03-31.
  15. ↑ "Joseph T. Coyle Receives Julius Axelrod Prize". www.sfn.org.
  16. 1 2 3 4 5 6 7 8 9 Google Scholar Author page, Accessed Jan. 28, 2022
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.